View Future GrowthWaverley Pharma 過去の業績過去 基準チェック /06Waverley Pharmaの収益は年間平均-3%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間37.8% 15.1%割合で 減少しています。主要情報-2.96%収益成長率-2.96%EPS成長率Biotechs 業界の成長51.09%収益成長率-15.06%株主資本利益率n/aネット・マージン-50.47%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • Jul 19Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, CanadaBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg CanadaBoard Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022.収支内訳Waverley Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TSXV:WAVE 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Mar 261-11031 Dec 25101030 Sep 25201030 Jun 25101031 Mar 251-11031 Dec 240-11030 Sep 240-21030 Jun 240-21031 Mar 240-21031 Dec 230-21030 Sep 231-11030 Jun 231-11031 Mar 231-11031 Dec 221-11030 Sep 222-11030 Jun 222-11031 Mar 222-11031 Dec 212-11030 Sep 212-11030 Jun 212-11031 Mar 211-11031 Dec 201-11030 Sep 201-11030 Jun 201-11031 Mar 201-11031 Dec 191-11030 Sep 191-11030 Jun 191-11031 Mar 190-11131 Dec 180-11130 Sep 180-31130 Jun 180-30131 Mar 180-30031 Dec 170-20030 Sep 17000031 Dec 160000質の高い収益: WAVEは現在利益が出ていません。利益率の向上: WAVEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: WAVEは利益が出ておらず、過去 5 年間で損失は年間3%の割合で増加しています。成長の加速: WAVEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: WAVEは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: WAVEの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 15:44終値2026/06/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Waverley Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.
Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Jul 19Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026Waverley Pharma Inc. announced that Haaris Uddin is resigning from his role as Chief Financial Officer (CFO) of the Company effective July 24, 2026 in order to pursue a professional opportunity outside the pharmaceutical industry. James Kinley, who is currently a director of the Company, has been named interim CFO and will assume the duties of Mr. Uddin upon his departure. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) and an experienced CFO in the life science industry.
Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canada
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canada
Board Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.
Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.
Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.
Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.
Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.
Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.
Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.
Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022.